Peter Cameron is the head of Technology Development at Caribou Biosciences, Inc. where he leads efforts to develop novel technologies for precision genome editing. He earned his Ph.D. in Molecular and Cellular Biology from the University of California, Berkeley and did postdoctoral work at The Scripps Research Institute in San Diego, where he developed novel genetic tools to manipulate neural circuits in the mouse brain. Following that, he was hired as a Scientist at Caribou, where he initially worked on a comprehensive, genome-wide method to measure CRISPR-Cas9 specificity (Cameron et. al., Nature Methods, 2017). More recently, Peter has worked on characterizing and optimizing multiple CRISPR-Cas systems for use as genome editing tools in human primary cells.
Emerging Therapeutics Showcase:
Caribou Biosciences, Inc. is a pioneer in genome editing, advancing the development of CRISPR-Cas technologies across many applications. Caribou is focused on the pre-clinical development of allogeneic immuno-oncology cell therapies and targeted engineering of gut microbes for the treatment of cancer.
Precision Genome Editing With Next-generation CRISPR-Cas9 Technology
In order to safely deploy genome editing for human therapeutics, we have developed high specificity CRISPR hybrid RNA-DNA (chRDNA) guides. Here, we will discuss implementing this technology to develop allogeneic immuno-oncology cell therapies.
The PMWC 2020 Emerging Therapeutics Showcase will provide a 15-minute time slot for selected companies and researchers in the CRISPR, Cell and Gene Therapy fields. Major advancements in safer cell- and gene-level editing technologies are bringing us closer toward cures for life-threatening disorders, from cancer to HIV to Huntington’s disease. Cell therapy, in which cellular material such as T cells capable of fighting cancer cells, is injected into a patient, has been demonstrated safe and effective. The popular new CRISPR tool that has been used to edit the genetic code of nearly any organism will have an enormous impact on human health. More than a dozen clinical trials employing CRISPR on human cells are already underway.